⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622405 | 1.00 | — | — | |
| SCHEMBL1623779 | 1.00 | — | — | |
| SCHEMBL29475546 | 1.00 | — | — | |
| SCHEMBL26622126 | 0.91 | CTSL (0.33) | — | |
| SCHEMBL18319305 | 0.88 | GRM5 (0.34) | — | |
| SCHEMBL1065926 | 0.86 | KAT2B (0.38) | — | |
| SCHEMBL2286907 | 0.84 | — | — | |
| SCHEMBL25394555 | 0.82 | CTSL (0.38) | — | |
| SCHEMBL3839876 | 0.82 | CTSL (0.38) | — | |
| SCHEMBL3999275 | 0.82 | CTSL (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250059214-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-118900839-A | Antiviral compounds and methods of making and using the same | 吉利德科学公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4444727-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382940-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023168254-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023107481-A1 | AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-114163437-A | Substituted pyrazolo [1,5-A ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-6696494-B2 | HUMAN IMMUNODEFICIENCY VIRUS | ENANTA PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030207934-A1 | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | ENANTA PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003034989-A2 | α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-5935976-A | Antiviral ethers of aspartate protease substrate isosteres | NOVARTIS CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| US-5807891-A | RETROVIRUSES | NOVARTIS AG (CH) | 1998-09-15 | — | — | US | disclosed |
| US-5663200-A | CARBAMOYL PEPTIDE DERIVATIVES AS VIRICIDES | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |